Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irinotecan Gastro-resistant Tablet. An Open Label Phase I, Dose Escalating Study Evaluating Safety, Tolerability and Pharmacokinetics of Oral Administration of Irinotecan in Adult Patients With Solid Tumors

Next Previous
Search
Trial Profile

Irinotecan Gastro-resistant Tablet. An Open Label Phase I, Dose Escalating Study Evaluating Safety, Tolerability and Pharmacokinetics of Oral Administration of Irinotecan in Adult Patients With Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Capecitabine (Primary) ; Irinotecan (Primary)
  • Indications Cervical cancer; Cholangiocarcinoma; Colon cancer; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Rectal cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 08 Apr 2019 According to an Ascelia Pharma media release, results from extension study were published in Cancer Chemotherapy and Pharmacology, a peer reviewed medical journal covering oncological pharmacotherapy.
    • 20 Feb 2019 Status changed from active, no longer recruiting to completed, according to an Ascelia Pharma media release.
    • 13 Nov 2018 According to an Ascelia Pharma media release, results from this trial have been newly published and are available on pubmed.gov titled "Oral administration of irinotecan in patients with solid tumours: an open-label, phase I, dose escalating study evaluating safety, tolerability and pharmacokinetics".

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top